United Therapeutics (UTHR) Tops Q2 EPS by 67c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
Revenue Growth %: -1.2%
Financial Fact:
Interest expense: -500K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Interest expense: -500K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.24, $0.67 better than the analyst estimate of $4.57. Revenue for the quarter came in at $596.5 million versus the consensus estimate of $524.18 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
